Dr Reddy's Labs, a company in the Pharmaceuticals industry, reported revenue of ₹8,698 crore and net profit of ₹913 crore for the September 2026 quarter.
Dr Reddy's Labs (NSE: DRREDDY) closed at ₹1,390.20 on 20 Nov 2026, up 11.3% over the past year. Its market capitalisation is ₹1,16,119 crore and it trades at 41.5 times earnings.
Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.